Insights into the mechanism of antiproliferative effects of primaquine-cinnamic acid conjugates on MCF-7 cells

dc.contributor.authorMabeta, Peaceful Lucy
dc.contributor.authorPavic, Kristina
dc.contributor.authorZorc, Branka
dc.contributor.emailpeace.mabeta@up.ac.zaen_ZA
dc.date.accessioned2018-10-08T05:50:30Z
dc.date.available2018-10-08T05:50:30Z
dc.date.issued2018-09
dc.description.abstractIn our previous paper, we showed that three primaquine-cinnamic acid conjugates composed of primaquine (PQ) residue and cinnamic acid derivatives (CADs) bound directly by an amide linkage (1) or through an acylsemicarbazide spacer (2 and 3) had significant growth inhibitory effects on some cancer cell lines. Compound 1 induced significant growth inhibition in the colorectal adenocarcinoma (SW620), human breast adenocarcinoma (MCF-7) and cervical carcinoma (HeLa) cell lines, while compounds 2 and 3 selectively inhibited the growth of MCF-7 cells. To better understand the underlying mechanisms of action of these PQ-CADs, morphological studies of the effects of test compounds on MCF-7 cells were undertaken using haematoxylin and eosin stain. Further analysis to determine the effects of test compounds on caspase activity and on the levels of apoptosis proteins were undertaken using the enzyme-linked immunosorbent assay (ELISA). Haematoxylin and eosin staining revealed that compounds 1 and 3 induced morphological changes in MCF-7 cells characteristic of apoptosis, while 2-treated cells were in interphase. Cell cycle analysis showed that cells treated with 1 and 3 were in sub-G1, while cells treated with 2 were mainly in interphase (G1 phase). Further, the study showed that the treatment of MCF-7 cells with 1 and 3 resulted in poly ADP ribose polymerase (PARP) cleavage as well as caspase-9 activation, indicating that they induced apoptotic cell death. We further investigated their effects on two important processes during metastasis, namely, migration and invasion. Compounds 1 and 3 inhibited the migration and invasion of MCF-7 cells, while compound 2 had a marginal effect.en_ZA
dc.description.departmentPhysiologyen_ZA
dc.description.librarianam2018en_ZA
dc.description.sponsorshipThe Croatian Science Foundation (project number IP-2014-09-1501), the National Research Foundation and the University of Pretoria.en_ZA
dc.description.urihttp://www.degruyter.com/view/j/acphen_ZA
dc.identifier.citationMabeta, P., Pavic, K. & Zorc, B. 2018, 'Insights into the mechanism of antiproliferative effects of primaquine-cinnamic acid conjugates on MCF-7 cells', Acta Pharmaceutica, vol. 68, no. 3, pp. 337-348.en_ZA
dc.identifier.issn1330-0075 (print)
dc.identifier.issn1846-9558 (online)
dc.identifier.other10.2478/acph-2018-0021
dc.identifier.urihttp://hdl.handle.net/2263/66773
dc.language.isoenen_ZA
dc.publisherDe Gruyter Openen_ZA
dc.rights© Authors. This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.en_ZA
dc.subjectPARPen_ZA
dc.subjectPrimaquine (PQ)en_ZA
dc.subjectHuman breast adenocarcinoma (MCF-7)en_ZA
dc.subjectBcl-2-associated death promoter (Bad)en_ZA
dc.subjectApoptosis proteins p53en_ZA
dc.subjectMigrationen_ZA
dc.subjectInvasionen_ZA
dc.subjectHybridsen_ZA
dc.subjectFluorineen_ZA
dc.subjectCanceren_ZA
dc.subjectInhibitionen_ZA
dc.subjectAntioxidanten_ZA
dc.subjectGrowthen_ZA
dc.subjectAgentsen_ZA
dc.subjectDerivativesen_ZA
dc.subjectBiological evaluationen_ZA
dc.subjectCinnamic acid derivative (CAD)en_ZA
dc.subjectColorectal adenocarcinoma (SW620)en_ZA
dc.subjectCervical carcinoma (HeLa)en_ZA
dc.subjectEnzyme-linked immunosorbent assay (ELISA)en_ZA
dc.titleInsights into the mechanism of antiproliferative effects of primaquine-cinnamic acid conjugates on MCF-7 cellsen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mabeta_Insights_2018.pdf
Size:
664.8 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: